Provention Bio Inc (Nasdaq: PRVB), a clinical stage biopharmaceutical company involved in intercepting and preventing immune-mediated diseases, announced yesterday that it has named Sherron Kell, MD, MPH as its new senior vice president of Clinical Development.
In the new role, Dr Kell will lead the PRV-031 (teplizumab) program, including the oversight of the Phase three PROTECT study and clinical support of anticipated regulatory submissions, and will report to Dr Eleanor (Leni) Ramos, chief medical and operating officer.
Dr Kell most recently served as vice president at Impax Pharmaceuticals. Previously, she was senior director, Clinical R&D at Johnson & Johnson, and scientific director at Novartis Pharmaceuticals.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer